 |
|
warfarin
A synthetic anticoagulant. Warfarin appears to inhibit the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand names: | | Athrombin-K
Compound 42
Co-Rax
Coumadin
Panwarfin
Rodex
WARF Compound 42 | | | | Abbreviation: | | WARF | | | | Chemical structure names: | | - 1-(4'-hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
- 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin
- 3-alpha-phenyl-beta-acetylethyl-4-hydroxycoumarin
- 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
| | |
|
|
